Information on this webpage has been carefully compiled to give insight and important facts regarding the significance of stem cell therapies. This information will help the patient evaluate specific treatment options for their ailments.

Though stem cell therapy is the most promising therapy for several devastating degenerative diseases, scientists are still under the process of understanding the several unanswered questions related to stem cells. Recent advances in stem cell science indicate that stem cell therapies have strong promise in curing various diseases. However, there are no guarantees of a 100% success rate of any therapy including stem cell therapy. With every passing day, encouraging reports validate the increasing rate of success for stem cell therapy in helping more and more people cure their ailments. GIOSTAR offers different stem cell therapies while current medical treatments do not give satisfactory results to the patient.

GIOSTAR’s medical team evaluates each prospective patient’s medical history to determine the eligibility for specific stem cell treatment. Patients planning to undergo stem cell therapy are required to apply for a detailed consultation. GIOSTAR uses autologous and allogeneic adult stem cells transplant to treat patients at its state-of-the-art facilities in strict compliance with the highest medical standards.

Types of Stem Cell used by GIOSTAR to treat diseases

Autologous
Stem cell collected from Bone marrow or from Peripheral stem cell

Autologous transplant means that the transplanted stem cell is derived from the person for whom the transplant is intended. In other words, the patient donates stem cells to himself. GIOSTAR takes advantage of this technique and developed its proprietary techniques to deliver stem cell to patients to treat several autoimmune and blood related diseases.

Allogeneic
Stem cell collected from Bone marrow or from Peripheral stem cell

An allogeneic transplant requires a donor, usually a sibling. The immune system uses certain determinants to identify things as self (autologous) or non-self (allogeneic). These determinants, also known as the HLA-system, will reject allogeneic tissue. Thus, tissue donors must be HLA-matched to the recipient in order for a successful transplant to take place. Furthermore, the recipient must be immunosuppressed to reduce the possibility of donor tissue (graft) rejection. Therefore, an allogeneic transplant is more complicated than an autologous transplant. GIOSTAR highly accomplished clinicians have the ability to use the allogeneic transplant with the great success and uses this technique where autologous stem cells transplant does not work.

Stem Cells from peripheral blood

To treat the diseases, GIOSTAR collectS the stem cells in a much simpler way using the peripheral blood stream. In patients, for whom bone marrow harvesting is impossible for some reason or another, GIOSTAR uses its highly advanced techniques and collect the stem cell form circulating peripheral blood and able to harvest and store over a several days to weeks by a techniques known as leukopheresis and cryopreservation respectively.

Peripheral blood stem cells accomplish this task much quicker. This accelerated blood cell recovery allows for a lower risk of infection and fewer transfusions compared to bone marrow stem cells. As a result, peripheral stem cell transplants in both the autologous and allogeneic transplant are much advanced. GIOSTAR scientists and clinicians are pioneers in using this method to treat the patients.

Placental umbilical cord stem cells
GIOSTAR uses cord blood stem cells deepening on the requirement of the treatment. The volume of blood and the total number of stem cells are generally small, but adults can reconstitute hematopoiesis with cord blood cells. Cord blood stem cells are immunologically naïve and therefore perfect HLA-matching is not required. More important are the number of stem cells and the volume of infused blood. Furthermore, large cord blood banks have made cord blood cells rapidly available providing an advantage compared to volunteer donor stem cells.

Mesenchymal stem cells
Mesenchymal stem cells, or MSCs, are multipotent stem cells that can differentiate into a variety of cell types, including: osteoblasts (bone cells), chondrocytes (cartilage cells), adipocytes (fat cells), and beta-cell to produce insulin. GIOSTAR scientists have the ability to collect, store, differentiate and use these cells to treat several degenerative diseases, where peripheral and bone marrow cells do not work.
After reviewing the condition of the patient(s), GIOSTAR scientists and clinicians decide the type of stem cell to be used for the treatment of a particular type of disease and patients.

Research: Advanced Stem Cell treatment under development by GIOSTAR Scientists

Human Embryonic Stem (ES) Cell
Embryonic stem cells, as their name suggests, are derived from embryos. Most embryonic stem cells are derived from embryos that develop from eggs that have been fertilized in vitro—in an in vitro fertilization clinic—and then donated for research or therapeutic purposes with informed consent of the donors. They are not derived from eggs fertilized in a woman’s body. These cells have capacity to make any human organ cell. GIOSTAR scientists have developed the method to differentiate these cells into specific types of cells such as blood, liver, heart, muscle, neural and skin cells and successfully tested to repair the damage organs in animals. Now GIOSTAR is working to develop the method to repair the organs in humans using these cells. GIOSTAR scientists have published their findings in the top rated peer review medical and research journals.

Induced pluripotent stem cells (iPSCs)

Induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell–like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells. Although these cells meet the defining criteria for pluripotent stem cells, it is not known if iPSCs and embryonic stem cells differ in clinically significant ways. Human iPSCs demonstrate important characteristics of pluripotent stem cells including expressing stem cell markers, from all three germ layers, and being able to contribute to many different tissues when injected into mouse embryos at a very early stage in development. GIOSTAR scientists are in advanced stage to develop the treatment of several degenerative diseases using iPSCs.

GIOSTAR uses autologous and allogeneic adult stem cells transplant to treat patients at its worldwide state of the art stem cell facilities at the highest medical standards.

GIOSTAR dose not use embryonic stem cell in any of its stem cell therapies for the patients.